NEWS. When Sciety was founded in 2014, the vision was clear – to bridge the gap between scientific breakthroughs and societal benefit. Ten years later, we have grown to become one of the Nordic region’s leading investors in life science and digital health, with over one billion SEK invested in
INSIGHT. In the pharmaceutical industry, contract development and manufacturing organizations (CDMOs) have taken on an increasingly central role. Over the past decade, these companies have shifted from being mere manufacturing partners to becoming drivers of innovation and technological development. To meet the changing demands of the pharmaceutical industry and the
At Sciety, we believe that the impact of scientific advancements should not be limited to the lab. This is why we support selected, innovative companies in life science and digital health. With deep expertise in life science, we are a long-term partner to prominent growth companies in the industry. Sciety
NEWS. Sciety supports innovative companies in life science and digital health. We help them grow and become successful, so that scientific breakthroughs in medicine and technology can become available to people all over the world. During the fall we continued our journey towards this goal, together with our portfolio companies.
NEWS. On November 9, 2023, Sciety invited its investor network to an exclusive event on the theme of future scenarios and opportunities within life science. The evening featured a panel discussion on data-driven precision medicine with Tommi Unkuri, Partner and Co-founder of Summa Equity; Mattias Häggblom, Sector Head for Healthcare,
PRESS RELEASE. Sciety och Sciety Venture Partners have invested SEK 54 million in Neogap Therapeutics (Neogap), a Swedish clinical-stage biotech company that develops personalised immunotherapy for cancer treatment with the help of two emerging technologies. The company has also been awarded roughly SEK 29 million in innovation funding from the